{"id":"W4200501854","doi":"10.1158/1535-7163.targ-21-p230","title":"Abstract P230: A phase 1/2 study of BLU-945, a highly potent and selective inhibitor of epidermal growth factor receptor (EGFR) resistance mutations, in patients with <i>EGFR</i>-mutant non-small cell lung cancer (NSCLC)","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"T790M; Osimertinib; Medicine; Epidermal growth factor receptor; Exon; Cancer research; EGFR inhibitors; Mutant; Lung cancer; Mutation; Gefitinib; Cancer; Oncology; Internal medicine; Erlotinib; Gene; Biology; Genetics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001037047,0.001912867,0.001470222,0.0004909575,0.0004843197,0.001317543,0.001188324,0.001233015,0.005551907],"category_scores_gemma":[0.0004842258,0.0006648423,0.001158096,0.0003808808,0.0007838577,0.0008398784,0.0003261064,0.002819736,0.001669271],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001018153,"about_ca_system_score_gemma":0.001833671,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002740743,"about_ca_topic_score_gemma":0.005468279,"domain_scores_codex":[0.9996923,0.00009890258,0.00001139615,0.00006899286,0.00003869617,0.00008958259],"domain_scores_gemma":[0.9997317,0.00002432538,0.0000312747,0.00001564773,0.00002345396,0.0001736275],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3818551,0.114062,0.008718358,0.001940453,0.00322509,0.001485501,0.0006550137,0.007006511,0.2132137,0.001162115,0.02945257,0.2372237],"study_design_scores_gemma":[0.3730114,0.5854437,0.01196823,0.00005588244,0.0009485883,0.001019996,0.0001400255,0.002718438,0.01598053,0.0004517769,0.008180954,0.00008046081],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9747677,0.005228961,0.002161081,0.0008892143,0.0002299105,0.005509057,0.004512989,0.0005703291,0.006130761],"genre_scores_gemma":[0.9764503,0.002988802,0.002262616,0.001326855,0.0001430196,0.002879446,0.005319835,0.0001119126,0.008517209],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005551907,"threshold_uncertainty_score":0.01857299,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0105822064170465,"score_gpt":0.289737410597893,"score_spread":0.2791552041808465,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}